This program will review the current state-of-the-art for breast cancer management, highlighting the key components of multi-disciplinary treatment to include breast pathology, surgical oncology, reconstructive surgery, medical oncology, and radiation oncology. The format of this program will consist of lectures by international experts in their fields.

The I-SPY2 clinical trial using an adaptive design to rapidly bring forth new agents in the neoadjuvant setting has been a significant advance in trial design, presented by the principal investigator of this trial. The prognostic significance of residual burden of cancer remaining in the breast after neoadjuvant chemotherapy has assumed increasing importance in recent times and will be a featured component of this seminar. Surgical treatment of the breast in patients who present with Stage IV disease has been controversial and will be discussed in detail. Recent advances in reconstructive microsurgery will be presented by one of the internationally prominent surgeons in the field. An update in the advances in partial breast and accelerated radiation techniques will be presented.

The understanding of the HER2 receptor continues to evolve, and the biology of the HER2 axis will be presented by one of the pioneers in our understanding of this phenomenon. Key talks in medical oncology will focus on HER2+ breast cancer therapeutics in the metastatic setting, the use of newer agents in metastatic ER+ cancers, and the evolution of immunotherapy as a central theme in the treatment of triple-negative breast cancer.

EDUCATIONAL OBJECTIVES

By the end of the course, participants will be able to:

• Understand the prognostic value of residual cancer remaining after neoadjuvant chemotherapy.
• Identify the unique features of the I-SPY2 adaptive trial design.
• Evaluate patients as candidates for oncoplastic surgical procedures and procedures to prevent and treat lymphedema after axillary operations.
• Outline the biology of the HER2 axis and its role in treating metastatic cancer.
• Describe the role of newer agents in treating metastatic ER+ cancers.
• Review newer concepts in treatment of triple negative breast cancers, including immunotherapy.
• Describe the evolving role of adjuvant partial breast radiation therapy, such as changes in dose/fractionation and technique.
• Understand the role of surgery for patients who initially present with Stage IV disease.

ACCREDITATION

The Keck School of Medicine of the University of Southern California is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Keck School of Medicine of the University of Southern California designates this Live Activity activity for a maximum of 7.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For more information please visit the official event page.